NCT06101667 Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)
| NCT ID | NCT06101667 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Tiantan Hospital |
| Condition | Acute Ischemic Stroke |
| Study Type | INTERVENTIONAL |
| Enrollment | 224 participants |
| Start Date | 2023-11-16 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 224 participants in total. It began in 2023-11-16 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to assess the efficacy and safety of endovascular treatment versus medical management in patients with acute basilar artery occlusion with extended time window of 24-72 hours from onset.
Eligibility Criteria
Inclusion Criteria: 1. Age≥18 years 2. Acute basilar artery occlusion confirmed by CTA, MRA, or DSA 3. Pre-stroke mRS of 0-2 4. NIHSS score ≥ 10 before randomization 5. Time interval from symptom onset (or last known well) to randomization within 24-72 hours 6. Diffusion-weighted imaging(DWI)-based pc-ASPECTS ≥ 6 and Pons-Midbrain Index (PMI) ≤3 7. Time from completion of DWI imaging to randomization is ≤3 hours 8. Each patient or their legal representative must provide written informed consent before enrolment Exclusion Criteria: 1. Any sign of intracranial hemorrhage (except microbleeds) on brain imaging prior to randomization 2. Complete cerebellar infarct with significant mass effect, or bilateral thalamic infarction as evidenced by baseline neuroimaging 3. CT or MRI evidence of intracranial tumor (except small meningioma and cerebral aneurysm \< 3mm in diameter) 4. Known or highly suspected chronic occlusion of basilar artery 5. History of contraindication for contrast medium (except mild rash) 6. Current pregnant or breast-feeding 7. Known to have dementia or psychiatric disease unable to complete neurological assessment and follow-up 8. Life expectancy is less than 3 months 9. Enrolled in another drug or device trial or expected to participate in another drug or device treatment trial within the following 3 months. 10. Any other condition (in the opinion of the site investigator) that inappropriate to participate this study
Contact & Investigator
Feng Gao, MD
PRINCIPAL INVESTIGATOR
Beijing Tiantan Hospital, Capital Medical Univerity
Frequently Asked Questions
Who can join the NCT06101667 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Ischemic Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06101667 currently recruiting?
Yes, NCT06101667 is actively recruiting participants. Contact the research team at dongri0514@sina.com for enrollment information.
Where is the NCT06101667 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06101667 clinical trial?
NCT06101667 is sponsored by Beijing Tiantan Hospital. The principal investigator is Feng Gao, MD at Beijing Tiantan Hospital, Capital Medical Univerity. The trial plans to enroll 224 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.